Evaluation of the efficacy and safety of alefacept in patients for whom conventional psoriasis therapies are ineffective or inappropriate - 13/08/11
Joel Sclessinger, MD, Skin Specialists PC, Omaha, NE, United States; Robert Pariser, MD, Virginia Clinical Research, Norfolk, VA, United States; Sharon Park, PharmD, Astellas Pharma U.S., Inc, Deerfield, IL, United States; Gina Wierz, Astellas Pharma U.S., Inc, Deerfield, IL, United States
Le texte complet de cet article est disponible en PDF. P2771 This study was originally sponsored by Biogen Idec. Astellas Pharma U.S., Inc. acquired ownership of Amevive effective April 14, 2006 and has subsequently supported the presentation of this study by providing material resources and editorial support. |
Vol 56 - N° 2S2
P. AB192 - février 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?